What DAFNA Capital Management LLC reported holding on Form 13F for the quarter ended Jun 30, 2026.
CIK 1389933 · Filed Aug 14, 2026
Values are as the managers reported them, in dollars.Open the Form 13F on SEC EDGAR
| Security | Shares | Change | Value | Of portfolio |
|---|---|---|---|---|
RVMDRevolution Medicines, Inc. | 562.6K | −3.1% | $105.4M | 20.1% |
SPDR S&P BIOTECH ETFETF | 196.5K | −38.3% | $31.1M | 5.9% |
| 2M |
| −16.8% |
| $28.5M |
| 5.4% |
STXSStereotaxis, Inc. | 13.7M | ±0% | $23.5M | 4.5% |
NKTRNektar Therapeutics | 318.4K | +92.7% | $22.2M | 4.2% |
DNLIDenali Therapeutics Inc. | 739K | +132.0% | $19M | 3.6% |
IDYAIDEAYA Biosciences, Inc. | 497.2K | +4.3% | $18.5M | 3.5% |
ATRCAtriCure, Inc. | 597.4K | ±0% | $16.7M | 3.2% |
XENEXenon Pharmaceuticals Inc. | 250.8K | ±0% | $15.1M | 2.9% |
CYTKCytokinetics Inc | 172K | −20.9% | $14.7M | 2.8% |
RCUSArcus Biosciences, Inc. | 441.8K | −0.5% | $13.6M | 2.6% |
ASNDAscendis Pharma A/S | 48.5K | New | $12.9M | 2.5% |
NBIXNeurocrine Biosciences Inc | 57.8K | −18.2% | $9.7M | 1.9% |
AXGNAxogen, Inc. | 209K | −16.4% | $9.7M | 1.8% |
PODDInsulet Corp | 61.9K | +469.2% | $9.4M | 1.8% |
EWTXEdgewise Therapeutics, Inc. | 226.8K | +102.1% | $9.2M | 1.8% |
BCAXBicara Therapeutics Inc. | 285K | −32.4% | $8.5M | 1.6% |
ISHARES NASDAQ BIOTECH INDXETF | 42.6K | −31.4% | $8.1M | 1.5% |
SNDXSyndax Pharmaceuticals Inc | 335.3K | +54.2% | $7.3M | 1.4% |
MPLTMapLight Therapeutics, Inc. | 171K | ±0% | $6.1M | 1.2% |
LRMRLarimar Therapeutics, Inc. | 2M | −1.0% | $6.1M | 1.2% |
IPSCCentury Therapeutics, Inc. | 2.4M | −1.4% | $5.9M | 1.1% |
DXCMDexCom Inc | 86.3K | ±0% | $5.8M | 1.1% |
IMVTImmunovant, Inc. | 149.5K | −0.7% | $5.8M | 1.1% |
INGNInogen Inc | 845.2K | ±0% | $5.5M | 1% |
TNDMTandem Diabetes Care Inc | 355.2K | New | $5.4M | 1% |
ALKSAlkermes plc. | 101.3K | −27.4% | $5.3M | 1% |
STOKStoke Therapeutics, Inc. | 130.9K | ±0% | $4.3M | 0.8% |
ALLOAllogene Therapeutics, Inc. | 2M | +46.0% | $4.2M | 0.8% |
BCRXBiocryst Pharmaceuticals Inc | 400.2K | −7.0% | $4M | 0.8% |
LKFTLakefront Biotherapeutics NV | 130.2K | ±0% | $3.9M | 0.7% |
KIDSOrthopediatrics Corp | 189.1K | +97.7% | $3.6M | 0.7% |
HELPHelus Pharma Inc. | 514.1K | +3.2% | $3.4M | 0.6% |
RAPPRapport Therapeutics, Inc. | 75K | ±0% | $3.1M | 0.6% |
KYMRKymera Therapeutics, Inc. | 27K | New | $3.1M | 0.6% |
PRQRProQR Therapeutics N.V. | 1.5M | −2.4% | $2.8M | 0.5% |
NGNENeurogene Inc. | 89K | +57.2% | $2.8M | 0.5% |
ANLAdlai Nortye Group Ltd. | 239.6K | New | $2.8M | 0.5% |
PRCTPROCEPT BioRobotics Corp | 120K | ±0% | $2.7M | 0.5% |
AQSTAquestive Therapeutics, Inc. | 645.9K | +75.3% | $2.7M | 0.5% |
CLDXCelldex Therapeutics, Inc. | 68.5K | ±0% | $2.5M | 0.5% |
GPCRStructure Therapeutics Inc. | 46.5K | ±0% | $2.5M | 0.5% |
ALGNAlign Technology Inc | 14K | −6.7% | $2.4M | 0.5% |
VKTXViking Therapeutics, Inc. | 59.5K | ±0% | $2.3M | 0.4% |
NGENNervgen Pharma Corp. | 1.1M | New | $2.2M | 0.4% |
BHVNBiohaven Ltd. | 137.6K | −83.7% | $2M | 0.4% |
MAZEMaze Therapeutics, Inc. | 65K | +85.7% | $1.9M | 0.4% |
ALECAlector, Inc. | 908.4K | ±0% | $1.8M | 0.3% |
LXEOLexeo Therapeutics, Inc. | 377.1K | ±0% | $1.8M | 0.3% |
PROFProfound Medical Corp. | 260.4K | −1.0% | $1.7M | 0.3% |
RNAAtrium Therapeutics, Inc. | 128K | New | $1.7M | 0.3% |
ANNXAnnexon, Inc. | 297.8K | +152.8% | $1.7M | 0.3% |
CTMXCytomX Therapeutics, Inc. | 438.4K | +90.6% | $1.6M | 0.3% |
RAREUltragenyx Pharmaceutical Inc. | 47.1K | −22.9% | $1.6M | 0.3% |
EPRXEupraxia Pharmaceuticals Inc. | 225.6K | New | $1.5M | 0.3% |
DSGNDesign Therapeutics, Inc. | 102.6K | New | $1.5M | 0.3% |
FATEFate Therapeutics Inc | 525K | −4.5% | $1.4M | 0.3% |
MDWDMediWound Ltd. | 94.4K | ±0% | $1.4M | 0.3% |
KURAKura Oncology, Inc. | 120.6K | −48.9% | $1.3M | 0.3% |
SPRYARS Pharmaceuticals, Inc. | 164.3K | +17.9% | $1.3M | 0.3% |
MLYSMineralys Therapeutics, Inc. | 44.5K | +15.6% | $1.2M | 0.2% |
IMTXImmatics N.V. | 117K | −48.2% | $1.2M | 0.2% |
TELATELA Bio, Inc. | 1.4M | ±0% | $1.1M | 0.2% |
PYPDPolyPid Ltd. | 207.9K | ±0% | $1.1M | 0.2% |
CRBPCorbus Pharmaceuticals Holdings, Inc. | 107.8K | New | $1M | 0.2% |
INSPInspire Medical Systems, Inc. | 18.2K | ±0% | $811.9K | 0.2% |
ACETAdicet Bio, Inc. | 93.8K | ±0% | $810.5K | 0.2% |
SPTXSeaport Therapeutics, Inc. | 32.4K | New | $703.7K | 0.1% |
MBXMBX Biosciences, Inc. | 11.8K | −93.3% | $651.9K | 0.1% |
BNTXBioNTech SE | 7K | ±0% | $651.4K | 0.1% |
ARTVArtiva Biotherapeutics, Inc. | 67.1K | New | $650.9K | 0.1% |
PLRXPliant Therapeutics, Inc. | 487K | ±0% | $555.2K | 0.1% |
SCYXScynexis Inc | 135.9K | New | $553K | 0.1% |
EDITEditas Medicine, Inc. | 170.5K | New | $552.3K | 0.1% |
OBIOOrchestra BioMed Holdings, Inc. | 126.8K | ±0% | $547.3K | 0.1% |
FHTXFoghorn Therapeutics Inc. | 111.9K | ±0% | $545.9K | 0.1% |
ARAYAccuray Inc | 1.7M | ±0% | $433.2K | 0.1% |
QTTBQ32 Bio Inc. | 32.9K | New | $419.1K | 0.1% |
NVCTNuvectis Pharma, Inc. | 20K | New | $367.8K | 0.1% |
CGENCompugen Ltd | 168.2K | −34.7% | $360K | 0.1% |
IBIOiBio, Inc. | 170.1K | −12.2% | $297.6K | 0.1% |
AUTLAutolus Therapeutics plc | 179.3K | ±0% | $286.9K | 0.1% |
BCYCBicycle Therapeutics PLC | 64.5K | ±0% | $273.4K | 0.1% |
TNYATenaya Therapeutics, Inc. | 300K | New | $221.7K | 0.1% |
VRCAVerrica Pharmaceuticals Inc. | 23.8K | −84.5% | $145.4K | 0.1% |
ENGNenGene Therapeutics Inc. | 74.7K | New | $129.1K | 0.1% |
KARDKardigan, Inc. | 5K | New | $119.3K | 0.1% |
ADCTADC Therapeutics SA | 77.1K | +6.9% | $82.5K | 0.1% |
